Abstract:Chronic liver injury is accompanied by a dysbalanced scarring process, termed fibrosis. This process is mainly driven by chronic inflammation and an altered activity of a multitude of different chemokines and cytokines, resulting in the infiltration by immune cells (especially macrophages) and increase of matrix-expressing cell types. These processes might lead to cirrhosis representing the end-stage of fibrosis. Recent clinical studies comprising patients successfully treated for viral hepatitis showed that liver fibrogenesis and even cirrhosis may be reverted. The hepatic capacity to remodel scar tissue and to revert into a normal liver follows specific mechanistic principles that include the termination of chronic tissue damage, shifting the cellular bias from inflammation to resolution, initiation of myofibroblast apoptosis or senescence and, finally, fibrinolysis of excess scar tissue. The plurality of molecular and cellular triggers involved in initiation, progression and resolution of hepatic fibrogenesis offers an infinite number of therapeutic possibilities. For instance, inflammatory macrophages can be targeted via inhibition of chemokine CCL2 or its receptor CCR2 (e.g., by cenicriviroc) as well as by transfer of restorative macrophage subsets. Another target is galectin-3 that acts at various stages along the continuum from acute to chronic inflammation. Profibrogenic cytokines (e.g., transforming growth factor-β), matricellular proteins (e.g., CCN1/CYR61) or signaling pathways involved in fibrogenesis offer further possible targets. Other options are the application of therapeutic antibodies directed against components involved in biogenesis or remodeling of connective tissue such as lysyl oxidase-like-2 or synthetic bile acids like obeticholic acid that activate the farnesoid X receptor and was antifibrotic in a phase 2 study (FLINT trial). Factors affecting the gut barrier function or the intestinal microbiome further expanded the repertoire of drug targets. In this review, we discuss novel concepts in resolution of hepatic fibrosis and focus on drug targets that might be suitable to trigger resolution of fibrosis.

Integrins in biliary injury and fibrosis

Integrins as a drug target in liver fibrosis

New Advances in the Molecular Mechanisms Driving Biliary Fibrosis and Emerging Molecular Targets

Advanced Therapies for Congenital Biliary Tract Malformation: from Bench to Bedside

Integrin Αvβ6 Contributes to the Development of Intestinal Fibrosis Via the FAK/AKT Signaling Pathway.

Therapeutic targets for cholestatic liver injury

Tight junction proteins and biliary diseases

Targeting integrins in hepatocellular carcinoma.

Liver Fibrosis: From Pathogenesis to Novel Therapies

Molecular Mechanisms of Fibrosis in Cholestatic Liver Diseases and Regenerative Medicine-Based Therapies

Targeting Integrins in Hepatocellular Carcinoma

Therapeutic Role of Bile Acids and Nuclear Receptor Agonists in Fibrosing Cholangiopathies

Comprehensive Review of Molecular Mechanisms during Cholestatic Liver Injury and Cholangiocarcinoma

The gut microbiota–bile acid axis: A potential therapeutic target for liver fibrosis

Central role for cholangiocyte pathobiology in cholestatic liver diseases

Integrins as attractive targets for cancer therapeutics

Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets

Novel and emerging therapies for cholestatic liver diseases

Mechanisms of Fibrosis in Primary Biliary Cholangitis

Modification of Chemokine Pathways and Immune Cell Infiltration as a Novel Therapeutic Approach in Liver Inflammation and Fibrosis

Biliary fibrosis is an important but neglected pathological feature in hepatobiliary disorders: from molecular mechanisms to clinical implications